Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Mar 12;209(3):507–520. doi: 10.1084/jem.20111424

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 Hamerlik et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

PMC Copyright notice

Figure 4. — VEGFR2 expression accounts for enhanced self-renewal, VEGF secretion, and viability of GSCs. Matched numbers of VEGFR2^L and VEGFR2^H cells from xenografted GBM specimens (T556 and T4121) were assayed for tumorsphere formation (A) and (T556 and T1966) viability (B). (A) Data are means ± SD of two independent experiments (n = 3; P < 0.001). (B) Viability of GSCs. Data are means ± SD of two independent experiments (n = 3; P < 0.001). (C) VEGF secretion by VEGFR2^H versus VEGFR2^L cells (GBM T556, 24 h) detected by ELISA (**, P < 0.01). (D) ELISA-detected VEGF secreted by VEGFR2^H GBM cells after neutralization by bevacizumab (0.5 mg/ml, 24 h), and inhibition of VEGFR2 kinase (SU1498, 5 µM), compared with nontreated controls (Con). Mean ± SD from two experiments in duplicate (***, P < 0.001).